Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;284(1):78-91.
doi: 10.1111/joim.12750. Epub 2018 Mar 26.

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver

C Schmitt  1   2   3 , H Lenglet  2   3 , A Yu  4 , C Delaby  5 , A Benecke  6   7 , T Lefebvre  1   2   3 , P Letteron  2 , V Paradis  2   8 , S Wahlin  9 , S Sandberg  10   11 , P Harper  12 , E Sardh  12 , A K Sandvik  13 , J R Hov  14 , A K Aarsand  10   11 , L Chiche  15 , C Bazille  16 , J-Y Scoazec  17 , J To-Figueras  18 , M Carrascal  19 , J Abian  19 , A Mirmiran  2   3 , Z Karim  2   3 , J-C Deybach  1   2   3 , H Puy  1   2   3 , K Peoc'h  2   3   20 , H Manceau  2   3   20 , L Gouya  1   2   3
Affiliations
Free article

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver

C Schmitt et al. J Intern Med. 2018 Jul.
Free article

Abstract

Background: Acute intermittent porphyria (AIP) is an inherited disorder of haem metabolism characterized by life-threatening acute neurovisceral attacks due to the induction of hepatic δ-aminolevulinic acid synthase 1 (ALAS1) associated with hydroxymethylbilane synthase (HMBS) deficiency. So far, the treatment of choice is hemin which represses ALAS1. The main issue in the medical care of AIP patients is the occurrence of debilitating recurrent attacks.

Objective: The aim of this study was to determine whether chronic hemin administration contributes to the recurrence of acute attacks.

Methods: A follow-up study was conducted between 1974 and 2015 and included 602 French AIP patients, of whom 46 had recurrent AIP. Moreover, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of Hmbs-/- mice chronically treated by hemin and extended the investigations to five explanted livers from recurrent AIP patients.

Results: The introduction of hemin into the pharmacopeia has coincided with a 4.4-fold increase in the prevalence of chronic patients. Moreover, we showed that both in animal model and in human liver, frequent hemin infusions generate a chronic inflammatory hepatic disease which induces HO1 remotely to hemin treatment and maintains a high ALAS1 level responsible for recurrence.

Conclusion: Altogether, this study has important impacts on AIP care underlying that hemin needs to be restricted to severe neurovisceral crisis and suggests that alternative treatment targeting the liver such as ALAS1 and HO1 inhibitors, and anti-inflammatory therapies should be considered in patients with recurrent AIP.

Keywords: acute intermittent porphyria; haem oxygenase 1; hemin; inflammation; iron overload.

PubMed Disclaimer

MeSH terms